# A Phase 2 Clinical Study to Evaluate the Efficacy and Safety of Frevecitinib (KN-002) in Patients With Severe Asthma

> **NCT07532265** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Kinaset Therapeutics Inc** · enrollment: 512 (estimated)

## Conditions studied

- Severe Asthma

## Interventions

- **DRUG:** Frevecitinib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07532265
- **Lead sponsor:** Kinaset Therapeutics Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-01
- **Primary completion:** 2027-11-30
- **Final completion:** 2027-11-30
- **Target enrollment:** 512 (ESTIMATED)
- **Last updated:** 2026-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07532265

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07532265, "A Phase 2 Clinical Study to Evaluate the Efficacy and Safety of Frevecitinib (KN-002) in Patients With Severe Asthma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07532265. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*